Global R&D Partner Aris Pharmaceuticals operates as a fast-growing chemistry service and intermediate API supplier serving 300 pharma, biotech, and agrochemical clients worldwide, indicating strong sales opportunities in custom synthesis, library production, and scale-up services for diverse R&D programs.

In-House Drug Programs The four in-house anti-viral R&D programs, including first-in-class HIV inactivators, highlight potential collaboration or licensing opportunities in early-stage antiviral discovery and development, appealing to partners seeking innovative mechanisms and early access to novel modalities.

Scale‑Up Capabilities Facilities in the US with kilo-scale synthesis and a Shanghai subsidiary pilot plant enable both small-group FTEs and bulk intermediates, presenting a compelling value proposition for customers needing scalable chemistry, from library synthesis to kilogram quantities.

Extensive Catalog A catalog of 8500+ scaffolds and building blocks with 60% in stock and most items ship within 1–2 weeks supports rapid procurement and bespoke synthesis, offering sales leverage for rapid material supply and custom intermediate needs.

Emerging Market Presence Revenue is under $1M with a diverse, global client base and locations in Bristol, PA and Shanghai, suggesting a growth opportunity to position Aris as a cost-effective, high-mix chemistry supplier for regional biotech clusters and multinational pharma pipelines seeking agile partners.